Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Meeting Abstract

Industry Collaboration

cited authors

  • Linhares, Yuliya; Freytes, Cesar; Cherry, Mohamad; Bachier, Carlos; Maris, Michael; Hoda, Daanish; Varela, Juan C.; Bellomo, Courtney; Cross, Scott; Essell, James; Fanning, Suzanne; Terebelo, Howard; Yimer, Habte; Courtright, Jay; Sharman, Jeff P.; Kostic, Ana; Vedal, Min; Ogasawara, Ken; Avilion, Ariel; Espinola, Ricardo; Yuan, Brenda; Mattar, Bassam

Publication Date

  • September 1, 2023

webpage

published in

category

keywords

  • CAR T-cell therapy
  • large B-cell lymphoma
  • lisocabtagene maraleucel
  • outpatient treatment
  • phase II

start page

  • S514

end page

  • S515

volume

  • 23